Blue Fin Capital’s VanEck Biotech ETF BBH Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$314K Hold
1,544
0.05% 138
2026
Q1
$290K Hold
1,544
0.05% 136
2025
Q4
$292K Sell
1,544
-26
-2% -$4.81K 0.05% 136
2025
Q3
$260K Hold
1,570
0.04% 135
2025
Q2
$241K Hold
1,570
0.04% 137
2025
Q1
$247K Hold
1,570
0.05% 127
2024
Q4
$246K Sell
1,570
-53
-3% -$8.92K 0.05% 126
2024
Q3
$288K Hold
1,623
0.05% 125
2024
Q2
$273K Sell
1,623
-24
-1% -$3.93K 0.05% 130
2024
Q1
$274K Sell
1,647
-138
-8% -$22.9K 0.06% 128
2023
Q4
$295K Sell
1,785
-799
-31% -$123K 0.08% 117
2023
Q3
$402K Sell
2,584
-149
-5% -$23.8K 0.12% 97
2023
Q2
$427K Hold
2,733
0.12% 97
2023
Q1
$434K Hold
2,733
0.14% 95
2022
Q4
$437K Sell
2,733
-427
-14% -$67.6K 0.16% 90
2022
Q3
$444K Hold
3,160
0.17% 87
2022
Q2
$460K Sell
3,160
-111
-3% -$16.5K 0.16% 88
2022
Q1
$530K Buy
+3,271
New +$530K 0.15% 85

Other funds holding BBH

Blue Fin Capital's BBH Position: Q2 2026 in Review

Blue Fin Capital held its VanEck Biotech ETF (BBH) position steady in Q2 2026 at 1,544 shares worth $314K. The position accounts for 0.05% of the portfolio, ranked #138.

Blue Fin Capital first reported a position in BBH in Q1 2022 and has held it in 18 quarters since. The position peaked at $530K in Q1 2022. 41 funds tracked by Wall St. Rank hold BBH as of Q2 2026.

  • Blue Fin Capital held 1,544 shares of VanEck Biotech ETF worth $314K as of Q2 2026.
  • Blue Fin Capital left its VanEck Biotech ETF share count unchanged in Q2 2026.
  • VanEck Biotech ETF made up 0.05% of Blue Fin Capital's portfolio in Q2 2026, its #138 holding.
  • Blue Fin Capital first reported a position in VanEck Biotech ETF in Q1 2022 and has held it in 18 quarters since.
  • Blue Fin Capital's VanEck Biotech ETF position peaked at $530K in Q1 2022.
  • 41 funds tracked by Wall St. Rank held VanEck Biotech ETF as of Q2 2026.

Based on Blue Fin Capital's 13F filing for Q2 2026, filed 4 Aug 2026.